Citations

Clear

6728 citation(s) found for "Li, Mark".

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
Anti-fibrinolytic strategies improve liver regeneration in mice and reduce post-hepatectomy liver failure in patients
Li, Zhihao , Wei, Zimu , Groeneveld, Dafna J. , Strilchuk, Amy W. , Flick, Matthew J., Dong, Yawen , Podrascanin, V. , Truty, Mark, Kendrick, Michael L., Cleary, S., Warner, Susanne G., Assinger, Alice, Kastrup, Christian J. , Karanicolas, Paul, Starlinger, P, Smoot, Rory L , Kastrup, Christian J , Luyendyk, James P , Li, Zhihao , Dong, Yawen , Flick, Matthew J. , Truty, Mark J. , Kendrick, Michael L. , Cleary, Sean P. , Warner, Susanne G. , Smoot, Rory L. , Assinger, Alice , Karanicolas, Paul J. , Luyendyk, James P.

Mayo Clinic

Blood Journal | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025029780 | PMID 42275251 Get It

Pharmacological plasminogen reduction enhanced liver regeneration experimentally and clinically. siRNA-induced plasminogen deficiency promoted hepatocyte proliferation after partial hepatectomy in mice, contrasting genetic deficiency models. In the HeLiX trial, tranexamic acid reduced post-hepatectomy liver failure odds, suggesting a novel therapeutic strategy.
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Wilson, Matthew R. , Lewis, Katharine L. , Kirkwood, Amy A., Cwynarski, Kate , Cheah, Chan Y. , El-Galaly, Tarec C., Villa, Diego , Savage, Kerry J. , Bobillo, Sabela , Smedby, Karin E. , Puckrin, Robert , Fox, Christopher P. , Bishton, Mark, Thanarajasingam, Gita , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Mel, Sanjay De , Preston, Gavin, Hawkes, Eliza A. , Clavert, Aline, Ku, Matthew , Narkhede, Mayur , Durot, Éric , Smith, Jeffrey , Eyre, Toby A. , Ghione, Paola , E Smedby, Karin , Harrysson, Sara , Trnĕný, Marek , Puckrin, Robert , Fox, Christopher P , Thanarajasingam, Gita , Doo, Nicole Wong , Hapgood, Greg , Soussain, Carole , Choquet, Sylvain , Dickinson, Michael , Talaulikar, Dipti , Preston, Gavin , Ahearne, Matthew , Hawkes, Eliza , Schorb, Elisabeth , Clavert, Aline , Ku, Matthew , Narkhede, Mayur S , Calimeri, Teresa , Durot, Eric , Smith, Jeffrey , Renaud, Loïc , McKay, Pamela , Eyre, Toby A , Savage, Kerry J , Cheah, Chan Yoon , Lewis, Katharine L , Kirkwood, Amy, El‐Galaly, Tarec Christoffer , Ghione, Paola , Trněný, Marek , Klánová, Magdalena , Bishton, Mark , Doo, Nicole Wong , Dickinson, Michael , Talaulikar, Dipti , Guidetti, Anna

Mayo Clinic

Journal of Clinical Oncology | June 11, 2026 | Volume: 44 | Issue: 24 | Pages: 2290-2302

10.1200/jco-26-00947 | PMID 42274647 Get It

PURPOSE In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months. RESULTS Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% v 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% v 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% v 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]). CONCLUSION To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.
Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings
Dhanam, Sreya , Taylor, Jack C. , Fregly, Ray, Kwang, Winnie, Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Kramer, Joel H. , Rosen, Howard J., Mackin, R. Scott , Weiner, Michael W., Nosheny, Rachel L. , Boxer, Adam L., Staffaroni, Adam M. , Registry, and the Brain Health, Staffaroni, Adam M , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Maruff, Paul , Boeve, Bradley F. , Boxer, Adam L. , Registry, and the Brain Health

Mayo Clinic

Alzheimer's & Dementia | June 11, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71580 | PMID 42273832 Get It

Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort. METHODS Adults without a record of cognitive impairment ( N = 1815; ages 18–92) were recruited from the University of California, San Francisco (UCSF) Brain Health Registry to complete three unsupervised smartphone cognitive testing sessions within 2 weeks. Reliability was assessed with correlations between sessions. Linear regression models tested associations of smartphone tasks with demographics, self‐ and informant‐rated cognitive concerns, and web‐based cognitive testing (Cogstate Brief Battery). RESULTS Adherence was high (82.2%) and usability favorable. Test–retest reliability was moderate to strong ( ρ ’s = 0.61–0.85, all p ’s < 0.001). Lower smartphone scores were associated with older age, lower education, cognitive concerns, and worse Cogstate performance. DISCUSSION Findings support the feasibility, reliability, and validity of remote digital assessments in adults without a record of cognitive impairment.
Diagnostic Accuracy of Multimodal LLMs in Differentiating Epileptic from Non-epileptic Events in Smartphone Recorded Videos (P2-11.005)
Patel, Anshum , Vallamchetla, Sai Krishna , Safa, Adrian , Tatit, Caroline, Kissinger‐Knox, Alicia, Roberts, Mark, Bestic, Olivia, Tatum, William, Freund, Brin, Tatit, Caroline P., Kissinger-Knox, Alicia M. , Tatum, William, Freund, Brin

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215770 Get It

Occipital Pain as a Symptom of Multiple Sclerosis: Prevalence, Clinical Subtypes, and Association With Upper Cervical Spinal Cord Demyelination (P4-19.007)
Coen, Bianca Albites, Kissoon, Narayan, Chowdhury, Purnashree , Keegan, Mark

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213132 Get It

Radiographic Determinants of Serum Neurofilament Light Chain Elevation in Multiple Sclerosis (P8-19.002)
Schleiss, Katherine, Chouhdry, Hira , Morris, Pearse, Baker, Matthew, Tobin, W., Flanagan, Eoin , Kantarci, Orhun, Keegan, Mark , Soldan, M. Paz, Pittock, Sean, banks, Samantha, Flanagan, Eoin P. , Kantarci, Orhun H. , Soldán, M. Mateo Paz , Pittock, Sean J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216614 Get It

Treatment of Headache with Occipital Nerve Blocks: Comparison Trial of Anesthetic with or Without Dexamethasone (P6-15.016)
Steel, Stephanie, Stern, Jennifer, Whealy, Mark, Cutrer, Michael, Kissoon, Narayan, Robertson, Carrie, Steel, Stephanie J., Stern, Jennifer I. , Whealy, Mark , Burke, Krista , Chiang, Chia‐Chun

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216592 Get It

Prospective Open-label Pilot Study of Rimegepant as a Treatment for Cluster Headache (P6-15.014)
Robertson, Carrie, Stern, Jennifer, Whealy, Mark, Kissoon, Narayan, Cutrer, Michael, Stern, Jennifer I. , Chiang, Chia‐Chun , Whealy, Mark , Burke, Krista

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216563 Get It